Propoxyphene

Summary

Propoxyphene (CHEMBL1213351) is an approved small-molecule opioid analgesic (ATC N02AC04); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02AC04
• Indications: 1 condition
• Chemistry: 339.5 Da · C22H29NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1213351
Name	Propoxyphene
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	10100
ChEBI	CHEBI:51173
ATC	N02AC04
Molecular formula	C22H29NO2
Molecular weight	339.5
InChIKey	XLMALTXPSGQGBX-GCJKJVERSA-N

SMILES: CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C

IUPAC name: [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate

ChEBI definition: The (1S,2R)-(+)-diastereoisomer of propoxyphene.

Pharmacological roles (ChEBI): opioid analgesic, μ-opioid receptor agonist.

Also known as: Algafan, D-propoxyphene, Depromic, Dextropropoxifeno, Dextropropoxyphen, Dextropropoxyphene, IDS-ND-004(SECT.2), J5.928E, Propoxyphene, d-, SK-65, (+)-Propoxyphene

Parent form; salt/anhydrous children: CHEMBL1237104, CHEMBL3989716

Patent coverage: 7,645 distinct patent families (31,640 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Histamine H2 receptor, 5-hydroxytryptamine receptor 2A, Alpha-1A adrenergic receptor, Mu-type opioid receptor, Delta-type opioid receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 9 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OPRM1	6.77	AC50	170	nM	CHEMBL_ACT_25147007
OPRM1	6.16	AC50	692.8	nM	CHEMBL_ACT_25157545
OPRK1	6.09	AC50	803.6	nM	CHEMBL_ACT_25129559
KCNH2	5.76	AC50	1739	nM	CHEMBL_ACT_25118069
HRH2	5.3	AC50	4954	nM	CHEMBL_ACT_25114482
HTR2A	5.27	AC50	5401	nM	CHEMBL_ACT_25173668
ADRA1A	5.09	AC50	8051	nM	CHEMBL_ACT_25138022

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).